---
title: "China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294273054.md"
description: "China Resources Pharmaceutical Group Ltd. announced that its subsidiary, CR Double-Crane, agreed to acquire a 23.50% stake in Lier Chemical for approximately RMB5.66 billion. This transaction makes China Resources the largest shareholder of Lier Chemical, turning it into a non-wholly-owned subsidiary. The deal is conditional and does not require shareholder approval under Hong Kong listing rules."
datetime: "2026-07-29T22:37:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294273054.md)
  - [en](https://longbridge.com/en/news/294273054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294273054.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical

An announcement from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.

China Resources Pharmaceutical Group Ltd., a Hong Kong-listed player in the pharmaceutical and healthcare products sector, is expanding its reach through its subsidiary CR Double-Crane. The subsidiary acts as a strategic investment arm, targeting equity stakes that align with the group’s broader life sciences and chemicals interests.

The company announced that CR Double-Crane has agreed to acquire a 23.50% stake in Lier Chemical for about RMB5.66 billion, becoming its largest shareholder and turning Lier Chemical into a non-wholly-owned subsidiary. The deal, classified as a discloseable transaction under Hong Kong listing rules and not requiring shareholder approval, remains conditional on agreed precedents, meaning completion is uncertain and investors are urged to exercise caution.

The acquisition is structured through purchases from Jiuyuan Group and Huacai Technology, reflecting China Resources Pharmaceutical’s strategy of securing significant influence in related chemical businesses. If completed, the transaction will deepen the group’s integration along the pharmaceutical and chemical supply chain, potentially enhancing operational synergies and reinforcing its industry positioning in mainland China and Hong Kong.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Pharmaceutical Group Ltd., through its subsidiary CR Double-Crane, operates in the pharmaceutical industry with a focus on manufacturing and distributing medicines and related healthcare products. The group is listed in Hong Kong and expands its footprint via strategic equity investments in sector-related companies to strengthen its market position and integrated healthcare portfolio.

CR Double-Crane serves as an investment and operating platform within the group, using acquisitions to deepen its presence across the wider life sciences and chemicals value chain. By pursuing controlling or major minority stakes, the company aims to enhance synergy, secure upstream resources and broaden its influence in key segments of the regional healthcare and pharmaceutical market.

**Average Trading Volume:** 9,665,698

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$30.16B

Learn more about 3320 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [002258.CN](https://longbridge.com/en/quote/002258.CN.md)
- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)
- [600062.CN](https://longbridge.com/en/quote/600062.CN.md)

## Related News & Research

- [China Resources Pharma unit tops bid to buy 23.5% stake in Lier Chemical](https://longbridge.com/en/news/292781868.md)
- [China Resources Pharmaceutical Completes RMB1.4 Billion Second Tranche of 2026 Bonds in China](https://longbridge.com/en/news/284352645.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain](https://longbridge.com/en/news/296217400.md)
- [11:06 ETPeptide Synthesis Market: USD 2.59 Billion by 2031, Driven by Therapeutic Demand & Advanced Synthesis Technologies, Says Mordor Intelligence](https://longbridge.com/en/news/296247020.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**